GV (Google Ventures)

Activity from announced rounds

Activity in this selectionMay 31, 2026 · May 1, 2026

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
6
Confirmed lead rounds
—
6 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$2.8B
6 disclosed · full round size, not this investor’s share

By stage

Series A3
Growth1
Seed1
Series B1

By primary sector

AI2
Biotech1
Cybersecurity1
Enterprise software1
Healthtech1

By country

United States3
United Kingdom2
France1

Rounds

6 in this selection
MokN

Protects organisations from credential theft and identity-based attacks through active identity recovery technology

$15MSeries A
Role not disclosed
Signos, Inc.

Offers an FDA-cleared AI-powered glucose monitoring system for weight management and metabolic health

$20MGrowth
Role not disclosed
Flick

AI-native filmmaking platform giving creators cinematic control to direct AI-generated films

$6MSeed
Role not disclosed
Nectar Social

Provides AI infrastructure for modern marketing

$30MSeries A
Role not disclosed
Recursive Superintelligence

Develops self-improving AI systems that autonomously enhance their own architecture and training algorithms

$650MSeries A
Role not disclosed
Isomorphic Labs

Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas

$2.1BSeries B
Role not disclosed